Influenza virus infection is an ongoing health and economic burden causing epidemics with
pandemic potential, affecting 5–30% of the global population annually, and is responsible …

The ability of the C3d component of complement to enhance antibody responses and protective
immunity to influenza virus challenges was evaluated using a DNA vaccine encoding a …

We developed a de novo protein design strategy to swiftly engineer decoys for neutralizing
pathogens that exploit extracellular host proteins to infect the cell. Our pipeline allowed the …

Human monoclonal antibodies are safe, preventive, and therapeutic tools that can be rapidly
developed to help restore the massive health and economic disruption caused by the …

Molecular understanding of serological immunity to influenza has been confounded by the
complexity of the polyclonal antibody response in humans. Here we used high-resolution …

Influenza viruses typically cause the most severe disease in children and elderly individuals.
However, H1N1 viruses disproportionately affected middle-aged adults during the 2013–…

There is limited knowledge on durability of neutralization capacity and antibody affinity
maturation generated following two versus three doses of SARS-CoV-2 mRNA vaccines in naïve …

SARS-CoV-2 has caused the global COVID-19 pandemic. Although passively delivered
neutralizing antibodies against SARS-CoV-2 show promise in clinical trials, their mechanism of …

Acute lung injury due to influenza infection is associated with high mortality, an increase in
neutrophils in the airspace, and increases in tissue myeloperoxidase (MPO). Because IL-17A …

Influenza virus is a highly infectious respiratory pathogen that results in severe morbidity and
mortality. The current licensed trivalent vaccine formulations in the US are made from virus …